<header id=002664>
Published Date: 2020-09-26 10:20:03 EDT
Subject: PRO/AH/EDR> COVID-19 update (415): vertical transmission, Fido, WHO, global
Archive Number: 20200926.7814181
</header>
<body id=002664>
CORONAVIRUS DISEASE 2019 UPDATE (415): VERTICAL TRANSMISSION, FIDO SNIFFER DOGS, WHO, GLOBAL
********************************************************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org

In this update:
[1] Vertical transmission
[2] Fido: Virus-sniffing dogs
[3] WHO: Daily new cases reported (as of 25 Sep 2020)
[4] Global update: Worldometer accessed 25 Sep 2020 22:41 EDT (GMT-4)

******
[1] Vertical transmission
[A] SARS-CoV-2 vertical transmission
Date: Thu 24 Sep 2020
Source: EBioMedicine [edited]
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30327-3/fulltext


Citation: Facchetti F, Bugatti M, Drera E, et al. SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of placenta. EBioMedicine. 2020; 59: 102951. https://doi.org/10.1016/j.ebiom.2020.102951

Abstract
--------
Background: The occurrence of transplacental transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains highly debated. Placental positivity for SARS-CoV-2 has been reported in selected cases, but infection or virus-associated disease of fetal tissues or newborns remains to be demonstrated.

Methods: We screened for SARS-CoV-2 spike (S) protein expression [in] placentas from 101 women who delivered between 7 Feb 2020 and 15 May 2020, including 15 tested positive for SARS-CoV-2 RNA, 34 tested negative, and 52 not evaluated as they did not meet testing criteria (32), or delivered before COVID-19 pandemic declaration (20). Immunostain for SARS-CoV-2 nucleocapsid (N) was performed in the placentas of all COVID-19-positive women. One placenta resulted positive for the SARS-CoV-2 S and N proteins, which was further studied by RNA-in situ hybridization and RT-PCR for S transcripts, and by electron microscopy. A comprehensive immunohistochemical and immunofluorescence analysis of the placental inflammatory infiltrate completed the investigations.

Findings: SARS-CoV-2 S and N proteins were strongly expressed in the placenta of a COVID-19 pregnant woman whose newborn tested positive for viral RNA and developed COVID-19 pneumonia soon after birth. SARS-CoV-2 antigens, RNA and/or particles morphologically consistent with coronavirus were identified in villous syncytiotrophoblast, endothelial cells, fibroblasts, in maternal macrophages, and in Hofbauer cells and fetal intravascular mononuclear cells. The placenta intervillous inflammatory infiltrate consisted of neutrophils and monocyte-macrophages expressing activation markers. Absence of villitis was associated with an increase in the number of Hofbauer cells, which expressed PD-L1. Scattered neutrophil extracellular traps (NETs) were identified by immunofluorescence.

Interpretation: We provide first-time evidence for maternal-fetal transmission of SARS-CoV-2, likely propagated by circulating virus-infected fetal mononuclear cells. Placenta infection was associated with recruitment of maternal inflammatory cells in the intervillous space, without villitis. PD-L1 expression in syncytiotrophoblast and Hofbauer cells, together with limited production of NETs, may have prevented immune cell-driven placental damage, ensuring sufficient maternal-fetus nutrient exchanges.

Evidence before this study: Several recent reports have addressed the question whether SARS-CoV-2 infection can be propagated from the mother to the fetus during pregnancy. Based on current data, evidence for vertical transmission of the SARS-CoV-2 infection is missing. Whereas detection of SARS-CoV-2 RNA in placental tissue has been recently documented, mechanisms limiting the spreading of virus infection to the newborn remain unknown. Distribution, composition and activation status of immune/inflammatory cells in placenta of COVID-19 pregnant women remain undetermined.

Added value of this study: This study analyzed by immunohistochemistry the expression of SARS-CoV-2 spike (S) protein in 101 placentas (including 15 from COVID-19-proved positive women) collected in Brescia, Italy during the SARS-Cov-2 pandemic. A single case showed robust expression of the S protein, as well as the N (nucleocapsid) protein in the syncytiotrophoblast. In addition, in situ hybridization for SARS-CoV-2 RNA demonstrated intense signal in the syncytiotrophoblast and in intervillous inflammatory cells, and ultrastructural analysis identified viral particles morphologically consistent with coronavirus localized in the cytoplasm of syncytiotrophoblast cells, in fetal capillary endothelium, fibroblasts, as well as in fetal intravascular mononuclear cells. Histopathological analysis of the immune/inflammatory cell infiltrate suggests that intervillous presence of activated monocyte-macrophages and neutrophils may represent a histological marker of SARS-CoV-2 infection of the placenta. This unique histopathological setting of the placenta coincided with early onset of COVID-19 disease in the newborn, consistent with vertical transmission of the infection.

Implications of all the available evidence: Together with previous reports, our study on 101 placentas from mothers collected in the COVID-19 pandemic stage documents that mother-to-fetus transmission of SARS-CoV-2 infection is a rare yet documented event. The findings provided in this study reveal the passage of SARS-CoV-2 across the maternal-fetal interface to infect fetal-derived cells of the placenta.

--
Communicated by:
Antonio Lavazza
Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna
Brescia, Italy
<antolava@bresciaonline.it>

[This is strong evidence demonstrating SARS-CoV-2 transmission across the placenta from mother to fetus. There is increasing evidence that SARS-CoV-2 can be transmitted in utero, highlighting the importance of caution by pregnant women in environments where virus exposure is possible. Fortunately, disease in neonates does not appear to be severe, unlike Zika virus. - Mod.LK]

---
[B] Brief reports
Date: September 2020
Source: Pediatric Infectious Diseases [abridged, edited]
https://journals.lww.com/pidj/Fulltext/2020/09000/Intrauterine_Transmission_of_SARS_COV_2_Infection.32.aspx


Citation: Sisman J, Jaleel MA, Moreno W, et al. Intrauterine transmission of SARS-COV-2 infection in a preterm infant. Pediatr Infect Dis J. 2020; 39(9): e265-7. doi: 10.1097/INF.0000000000002815.

Abstract: We present a preterm infant who developed a fever and mild respiratory disease on the 2nd day of life. Infant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nasopharyngeal testing was positive at 24 and 48 hours of life. Placenta histopathology revealed SARS-CoV-2 infection by electron microscopy and immunohistochemistry. Further understanding of the risk factors that lead to in utero transmission of SARS-CoV-2 infection is needed.

Discussion: This report represents a case of congenital SARS-CoV-2 infection in an infant born via vaginal delivery to a mother with COVID-19 presenting primarily with gastrointestinal manifestations. It is unlikely that the respiratory distress observed in this infant was due to prematurity because it did not start until the 2nd day of life. Although the infant had an elevated neutrophil count, the lymphocyte count was decreased, as has been described in adults with COVID-19. Viral hepatitis was excluded by the absence of elevated liver transaminases.

Early reports of obstetric and neonatal outcomes of pregnant women with COVID-19 suggested that SARS-CoV-2 infection in pregnancy results in infants with no clinical features of infection and negative nasopharyngeal testing (9; see full list of references at source URL). However, there are now an increasing number of neonatal cases with possible congenital or intrapartum-acquired neonatal SARS-CoV-2 infection. To date, 8 infants with SARS-CoV-2 virus infection proximate to delivery have been reported (2-6).

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The mother had exacerbating conditions during pregnancy with maternal class B diabetes mellitus, obesity, and late latent syphilis. But both mother and baby fully recovered and were never severely ill, although they did require oxygen and fluids. - Mod.LK]

---
[C] Possible COVID-19 pandemic and pregnancy: vertical transmission is not excluded
Date: September 2020
Source: Pediatric Infectious Diseases [abridged, edited]
https://journals.lww.com/pidj/Fulltext/2020/09000/Possible_Coronavirus_Disease_2019_Pandemic_and.30.aspx


Citation: Marzollo R, Aversa S, Prefumo F, et al. Possible coronavirus disease 2019 pandemic and pregnancy: vertical transmission is not excluded. Pediatr Infect Dis J. 2020; 39(9): e261-e2. doi: 10.1097/INF.0000000000002816.

Abstract: The COVID-19 outbreak has a growing impact on global health; vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still controversial. In this article, we describe a case of vertical transmission of SARS-CoV-2 in a newborn with respiratory and gastrointestinal symptoms.

Introduction: Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can be transmitted from the mother to the fetus is still controversial. Chen et al. (3; see source URL for full list of references) described 9 cases of COVID-19 pneumonia in pregnancy: All women underwent caesarean section, with no evidence of vertical transmission. Zhu et al. (4) reported on 10 neonates of mothers with COVID-19 pneumonia, 2 of whom delivered vaginally: All these babies were symptomatic, but there was no demonstration of vertical transmission of the virus. In a case series, 3 babies of 3 women affected by COVID-19 pneumonia were reported negative for SARS-CoV-2 on oropharyngeal swab, umbilical cord blood, and serum (5). Two other case reports showed no evidence of mother-to-child transmission in utero or at delivery, either by caesarean section or vaginally (6-8). Dong et al. (9) reported a case of an asymptomatic infant born to a mother with COVID-19 pneumonia, with elevated immunoglobulin M antibodies to SARS-CoV-2 at 2 hours of age, but negative real-time polymerase chain reaction (RT-PCR) on nasopharyngeal swabs. Similarly, Zeng H et al. (10) describes the course of 6 mothers who gave birth to 6 infants; 2 of them had raised immunoglobulin M, but RT-PCR for SARS-CoV-2 was negative on throat swabs and blood. Recently Zeng L et al. (11) reported 3 cases of early-onset neonatal COVID-19; those neonates tested positive for SARS-CoV-2 on day 2 of life on both nasopharyngeal and anal swab.

Case report: We report a case of early-onset neonatal COVID-19 infection in a male infant born at 38 weeks of gestation by induced vaginal delivery. A 29-year-old primiparous woman, with a history of idiopathic thrombocytopenia during the 1st trimester of pregnancy developed fever 9 days before delivery. Seven days later, she was admitted to our hospital with fever (38.0 deg C/100.4 deg F) and slight parenchymal thickening in the left retrocardiac region at chest roentgenogram. The SpO2 was 97%-100%. A nasopharyngeal swab tested positive for SARS-CoV-2 at RT-PCR. She was treated with lopinavir/ritonavir, hydroxychloroquine, azithromycin, and ceftriaxone. Since thrombocytopenia had become severe, intravenous immunoglobulins were also administered and labor induction started with dinoprostone vaginal pessary. Rupture of the membranes occurred during labor; after early cord clamping, the newborn was transferred by a midwife not involved in the care of the mother to a dedicated neonatal area. Apgar index was 9 at 1 minute and 10 at 5 minutes; birth weight was 2840 â€‰g (6.26 lb). Skin-to-skin contact and breast-feeding were not possible immediately after delivery because of postpartum maternal hemorrhage. The newborn was admitted to the nursery, and the result of the 1st RT-PCR test for SARS-CoV-2 on nasopharyngeal swab was inconclusive (amplification of less than 3 genes). In the nursery, the baby was fed with formula.

Approximately, at 12 hours of life, he began to show signs of feeding intolerance with abdominal distension and hyporeactivity, which rapidly worsened. The newborn was transferred to the neonatal intensive care unit (NICU), enteral feeding was stopped, and total parenteral nutrition and antibiotics (ampicillin and gentamycin) were started via an umbilical venous catheter. A roentgenogram of chest and abdomen showed no pulmonary abnormalities and generalized intestinal dilatation and some air fluid levels. Blood cultures performed at birth and at NICU admission were negative; C-reactive protein was normal at 2 different times; blood count was normal at birth, but mild leukopenia (5170/mcL; normal values, 9000-30 000/mcL), significant increase of lactate dehydrogenase (1065 U/L; normal values, 290-775 U/L), and mild increase of troponin T were evident at 3 days of life. Nasopharyngeal swab RT-PCR for SARS-CoV-2, repeated at 36 hours of life, was positive. The baby's clinical condition and gas exchange worsened on the following day, with development of partially compensated respiratory acidosis and mild hyperlacticaemia. Oxygen saturation was normal. Low-flow nasal cannula (fraction of inspired oxygen, 0.21) was administrated. Chest roentgenogram showed mild bilateral increased interstitial markings, and on physical examination abdominal distension was evident. A roentgenogram contrast study of the digestive tract was conducted, which showed normal progression of the contrast material to the rectum. During the night, the baby needed endotracheal intubation and mechanical ventilation (fraction of inspired oxygen, 0.21). A new chest roentgenogram showed further increase of interstitial markings on the base of the left lung. RT-PCR for SARS-CoV-2 on tracheal aspiration was also positive. The clinical condition of the baby gradually improved, a 3-day course of chloroquine was started, and mechanical ventilation was stopped 36 hours after intubation. Enteral feeding was gradually increased without further problems. A new RT-PCR for SARS-CoV-2 on nasopharyngeal (at 17 days of life) and on anal swab (at 19 days of life) were positive. The infant was discharged in good clinical condition 18 days after birth. Two different control nasopharyngeal swabs repeated approximately at 1 month of life were negative.

Discussion: This case confirms the possibility of transmission of SARS-CoV-2 from the mother to the newborn. Maternal fever for 9 days, the absence of postnatal mother-baby contact, and the early onset of neonatal symptoms may suggest a transplacental transmission rather than birth canal infection.

The major limitation in our study was that serologic tests and RT-PCR on amniotic fluid, placenta, and vaginal secretions were not performed. This is, to our knowledge, the 1st case of vertical transmission of SARS-CoV-2 with positive RT-PCR on nasopharyngeal swab at birth.

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[This report has a good summary of prior studies. - Mod.LK]

---
[D] Additional reading
- Probable vertical transmission of SARS-CoV-2 infection.
Demirjian A, Singh C, Tebruegge M, et al. Pediatr Infect Dis J. 2020; 39(9): e257-60. doi: 10.1097/INF.0000000000002821.

- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vertical transmission in neonates born to mothers with coronavirus disease 2019 (COVID-19) pneumonia.
Hu X, Gao J, Luo X, et al. Obstet Gynecol. 2020; 136(1): 65-7. doi: 10.1097/AOG.0000000000003926.

- The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis.
Diriba K, Awulachew E, Getu E. Eur J Med Res. 2020; 25(1): 39. doi: 10.1186/s40001-020-00439-w.

- Neonatal resuscitation where the mother has a suspected or confirmed novel coronavirus (SARS-CoV-2) infection: suggestion for a pragmatic action plan.
Trevisanuto D, Moschino L, Doglioni N, et al. Neonatology. 2020; 117(2): 133-40. doi: 10.1159/000507935.

- A message from the human placenta: structural and immunomodulatory defense against SARS-CoV-2.
Kreis NN, Ritter A, Louwen F, Yuan J. Cells. 2020; 9(8): 1777. doi: 10.3390/cells9081777.

******
[2] Fido: Virus-sniffing dogs
Date: Fri 25 Sep 2020 11:10 EDT
Source: The Guardian [abridged, edited]
https://www.theguardian.com/world/2020/sep/25/any-breed-could-do-it-dogs-might-be-covid-testers-best-friend


It is simple and pain-free, could be used to test for coronavirus in care homes, airports and schools, and might just be more realistic than the UK government's GBP 100 billion (USD 127 billion) "Operation Moonshoot" mass screening plan. Its name? Fido.

Around the world -- from the UK to Finland, Spain, Brazil, Lebanon and Australia -- teams of researchers are training dogs to sniff out COVID-19. And some say the idea of training hundreds of thousands of canine noses to check for coronavirus is not as far-fetched as it may sound.

How do dogs do it? At Finland's Helsinki airport, where 4 COVID-19 sniffer dogs have begun work in a state-funded pilot scheme, passengers dab their skin with a wipe, which is placed in a beaker next to others containing control scents. If the dog detects the virus -- shown by yelping, pawing, or lying down -- the passenger takes a free swab test to verify its verdict.

Speaking to the Guardian, scientists said any breed could in theory be trained -- a process that takes between 2 and 10 weeks -- raising the prospect of pet canines joining an army of COVID sniffers. Professor Dominique Grandjean, of the national veterinary school of Alfort in France, who is leading a research team using bomb detection, cancer detection, and search and rescue dogs, said the canines were not sniffing the virus itself but rather tell-tale volatile chemicals produced when the virus infects cells, and released by the body. The chemicals should be produced whether or not an infected person has symptoms, and only if the virus is active -- suggesting that unlike current lab techniques, dogs are unlikely to pick up "dead" virus, Grandjean said.

Results from Grandjean and his colleagues, which are yet to be peer-reviewed, show sweat samples from COVID patients were correctly identified by 8 dogs at least 83% of the time, with some making a correct identification in 100% of the trials they underwent. The team say they have since validated their approach in 3 separate trials, although the results have yet to be published. Grandjean thinks the approach has potential to become widespread. "We can have one dog per retirement house that is trained and this dog would be able every single morning to check everybody, just by walking by," he said. His team plans to work with a French organisation to provide COVID-sniffing dogs to care homes.

Another research project is underway in Germany, using saliva rather than sweat samples. In a pilot study using 8 dogs and 1012 samples, the animals correctly spotted COVID-positive samples 83% of the time on average, and correctly identified COVID-negative samples 96% of the time. The lead author of the research, Professor Holger Volk of the University of Veterinary Medicine in Hanover, said the current "have you got it" COVID lab test correctly identified the virus was present about 75% of the time, and correctly ruled it out almost 100% of the time.

Volk said his team was working on whether the dogs can distinguish between different viruses, and Grandjean was upbeat. "Different types of virus have different volatile organic compounds coming from cell cultures, meaning [these] compounds are specific to each virus," he said, although he noted this had yet to be proved for SARS-CoV-2. Dr. David Strain, a senior clinical lecturer at the University of Exeter medical school, said the canine approach was likely to be hugely beneficial.

[Byline: Nicola Davis]

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The dogs trained to detect SARS-CoV-2 could be deployed to locations where screening of individuals is important. Even if the scent is not specific to SARS-CoV-2 and dogs also detect cold coronaviruses or other closely related viruses, it still could serve as an excellent screening tool, to be followed up by a molecular assay, especially a point-of-care rapid assay as has been championed by Michael Mina, among others. Any way that infectious individuals can be identified and separated out will help control spread of virus to susceptible individuals. Dogs have a history of being used to sniff out disease, and training them seems to be fast and not difficult. - Mod.LK]

******
[3] WHO: Daily new cases reported (as of 25 Sep 2020)
Date: Fri 25 Sep 2020
Source: WHO [abridged, edited]
https://covid19.who.int/table


*Daily case reports as of 25 Sep 2020 17:34 CEST

Surveillance
------------
WHO region (no. countries/territories):
Total confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)
---------------------------
Western Pacific Region (19): 594 542 (2876) / 12 938 (53)
European Region (61): 5 527 148 (67 496) / 233 286 (652)
South East Asia Region (10): 6 530 873 (94 479) / 108 181 (1339)
Eastern Mediterranean Region (22): 2 304 121 (18 556) / 59 532 (341)
Region of the Americas (54): 15 987 906 (115 485) / 540 774 (3826)
African Region (49): 1 165 325 (4113) / 25 307 (105)
Cases on an international conveyance (Diamond Princess): 712 (0) / 13 (0)

Confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)
Grand total: 32 110 656 (303 005) / 980 031 (6316)

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The number of countries and territories reporting confirmed cases of COVID-19 to WHO remains at 215.

Data by country, area, or territory for 25 Sep 2020 can be accessed at https://promedmail.org/wp-content/uploads/world-pdf/WHO%20daily%20tablesSept25_1601068403.pdf.

- The Americas region reported 38.1% of daily case numbers and 60.6% of the daily deaths reported in the past 24 hours, maintaining its position as the most severely affected region, having reported more than 15.9 million cases. The USA and Brazil dominate, followed by Argentina, Colombia, Peru, and Mexico. Other countries and territories reporting more than 1000 cases in the past 24 hours include Chile, Costa Rica, Puerto Rico, Ecuador, and Canada.

- The European region reported 22.3% of daily case numbers and 10.3% of the daily deaths reported in the past 24 hours, and total cumulative cases reported exceed 5.5 million. Countries not reporting cases today (25 Sep 2020) include Israel and Belgium. France dominates, followed by Spain, Russia, the UK, Ukraine, the Czech Republic, the Netherlands, and Germany. Other countries reporting more than 1000 cases in the past 24 hours include Turkey, Italy, Romania, and Poland.

- The Eastern Mediterranean region reported 6.1% of daily case numbers and 5.4% of the deaths reported in the past 24 hours, having reported a cumulative total of greater than 2.3 million cases. Iraq remains the dominant country, followed by Iran, Morocco, Lebanon, and the UAE. Other countries reporting more than 500 cases include Tunisia, Pakistan, Palestinian Authority, Bahrain, Oman, Kuwait, Jordan, and Libya.

- The African region reported 1.4% of daily case numbers and 1.7% of the deaths reported in the past 24 hours and has reported more than 1.1 million cases. South Africa dominates, followed by Ethiopia, Botswana, Uganda, Kenya, Mozambique, Nigeria, and Angola.

- The Western Pacific region reported 0.95% of daily case numbers and 0.84% of the deaths reported in the past 24 hours, having reported a cumulative total of 0.59 million cases. The Philippines continues to dominate followed by Japan, South Korea, and Malaysia.

- The South East Asia region reported 31.2% of the daily newly reported cases and 21.2% of reported deaths in the past 24 hours, having reported a cumulative total of more than 6.5 million cases. India continues to dominate, followed by Indonesia, Bangladesh, Nepal, and Myanmar.

On the Overview tab at the WHO source URL, the epidemic curve of confirmed COVID-19 cases by WHO region, 30 Dec 2019 through 25 Sep 2020 is an excellent visual representation of the pandemic. - Mod.MPP]

******
[4] Global update: Worldometer accessed 25 Sep 2020 22:41 EDT (GMT-4)
Date: Fri 25 Sep 2020
Source: Worldometer [edited]
https://www.worldometers.info/coronavirus/#countries


[For those who wish to see the detailed global data, a snapshot of the Worldometer table at the time we accessed it is available at https://promedmail.org/wp-content/uploads/world-pdf/SEPT25DATASET_1601091615.pdf.

A 7-day series of cumulative data reported by countries, territories, and reporting entities can be found at https://promedmail.org/wp-content/uploads/world-pdf/SEPT25WORLD7_1601091703.pdf. - Mod.MPP]

Total number of reported deaths: 993 413
Total number of worldwide cases: 32 758 340
Number of newly confirmed cases in the past 24 hours: 349 836

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The USA, India, and Brazil are still the most severely affected countries in terms of cumulative case counts and daily new case confirmations, with India now in the 2nd position followed by Brazil. In the past 24 hours, these 3 countries -- India (85 468), followed by the USA (58 713) and Brazil (32 670) -- account for over half of all confirmed cases globally (54.5%) and 50.6% of all newly confirmed cases in the past 24 hours. As the daily reports from each of the 3 countries have been dropping, other countries are reporting more newly confirmed cases. A global total of 5689 deaths were reported in the past 24 hours (24-25 Sep 2020).

Countries reporting more than 5000 newly confirmed cases in the past 24 hours include India, USA, Brazil, Spain (30 989), France (15 797), Argentina (12 969), Colombia (7494), Russia (7212), UK (6873), Israel (5784), Peru (5654), and Mexico (5401); 36 countries have reported more than 1000 cases in the past 24 hours. Eight of the top 20 countries reporting the highest daily newly confirmed cases are from the European region and 6 were from the Americas region (unchanged from yesterday).

Comparing the 7-day averages of daily confirmed cases from the past 7 days and those from 8-14 days ago, there is an increase in case counts by 1.1%, while daily reported deaths have increased by 0.40%.

Impression: While the global 7-day averages appear to have plateaued, when one looks at the country-by-country figures, the 3 major countries -- the USA, India and Brazil -- have decreased their daily newly confirmed cases, but other countries have increased transmission, especially in Europe and the Americas. - Mod.MPP]
See Also
COVID-19 update (414): animal, Netherlands (LI), Denmark (ND), farm mink, spread 20200925.7813579
COVID-19 update (413): interferon type I, Saudi Arabia Umrah, WHO, global 20200925.7811505
COVID-19 update (412): surfaces, pregnancy, WHO, global 20200924.7808613
COVID-19 update (411): monoclonal Ab, conval plasma, pooled saliva, WHO, global 20200923.7805033
COVID-19 update (410): ACE inhibitors and ARBs, WHO COVAX plan, WHO, global 20200922.7801717
COVID-19 update (400): lockdowns, influenza co-infections WHO, global 20200914.7776512
COVID-19 update (350): USA (TX) animal, cat 20200808.7658191
COVID-19 update (300): Korea antibodies, China asymptomatic index case, WHO 20200703.7536146
COVID-19 update (250): selected countries 20200610.7448037
COVID-19 update (200): global, Yemen, WHO 20200522.7364937
Undiagnosed pediatric inflammatory syndrome (06): COVID-19, heart, young adults 20200522.7364506
Undiagnosed pediatric inflammatory syndrome (05): Europe, USA, COVID-19 assoc 20200518.7340554
Undiagnosed pediatric inflammatory syndrome (04): USA, UK, PMIS, fatal 20200509.7315405
Undiagnosed pediatric inflammatory syndrome (03): USA, Europe, COVID-19 susp, RFI 20200505.7299876
COVID-19 update (150): global, USA state prisons, WHO 20200502.7290671
COVID-19 update (100): China, S. Korea & high local transmission countries 20200413.7217806
COVID-19 update (50): China (Hong Kong) animal dog, 2nd case PCR positive, OIE 20200323.7129951
COVID-19 update (01): China, global, EVZD, reporting criteria, WHO 20200213.6984084
Novel coronavirus (42): China, global, COVID-19, SARS-CoV-2, WHO 20200211.6979942
Novel coronavirus (41): China, global, clinical pics, asymptomatic trans., WHO 20200210.6976117
Novel coronavirus (40): animal reservoir, pangolin poss intermediate host, RFI 20200210.6972104
Novel coronavirus (30): updates, China, Viet Nam, research 20200202.6945658
Novel coronavirus (20): China, wildlife trade ban 20200127.6922060
Novel coronavirus (10): China (HU, GD, BJ) 20200119.6898567
Novel coronavirus (01): China (HU) WHO, phylogenetic tree 20200112.6885385
Undiagnosed pneumonia: China (HU) (10): genome available, Hong Kong surveill. 20200111.6883998
Undiagnosed pneumonia: China (01): (HU) wildlife sales, market closed, RFI 20200102.6866757
2019
----
Undiagnosed pneumonia: China (HU): RFI 20191230.6864153
and other items in the archives
.................................................lm/lk/mpp/rd/lm
</body>
